TALK vs CLOV

For growth investors, Clover Health Investments, Corp.

(CLOV) is the stronger pick with 40. 3% revenue growth year-over-year, versus 22. 0% for Talkspace, Inc. (TALK). Talkspace, Inc. (TALK) offers the better valuation at 129. 5x trailing P/E (38. 2x forward), making it the more compelling value choice. Analysts rate Talkspace, Inc. (TALK) a "Hold" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Talkspace, Inc.

is actually cheaper at 38. 2x.

Over the past 5 years, Talkspace, Inc.

(TALK) delivered a total return of -47. 7%, compared to -67. 3% for Clover Health Investments, Corp. (CLOV). Over 10 years, the gap is even starker: TALK returned -48. 7% versus CLOV's -72. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Talkspace, Inc.

(TALK) is the lower-risk stock at 0. 86β versus Clover Health Investments, Corp. 's 1. 22β — meaning CLOV is approximately 42% more volatile than TALK relative to the S&P 500.

By revenue growth (latest reported year), Clover Health Investments, Corp.

(CLOV) is pulling ahead at 40. 3% versus 22. 0% for Talkspace, Inc. (TALK). Over a 3-year CAGR, TALK leads at 24. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Talkspace, Inc.

(TALK) is the more profitable company, earning 3. 4% net margin versus -4. 4% for Clover Health Investments, Corp. — meaning it keeps 3. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TALK leads at 1. 4% versus -4. 4% for CLOV. At the gross margin level — before operating expenses — TALK leads at 43. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Talkspace, Inc.

(TALK) trades at 38. 2x forward P/E versus 65. 9x for Clover Health Investments, Corp. — 27. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CLOV: 18. 1% to $3. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Talkspace, Inc.

(TALK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 86)). Both have compounded well over 10 years (TALK: -48. 7%, CLOV: -72. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.